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Abstract
Background: Food allergy is an important public health problem because it affects children and adults, can be
severe and even life-threatening, and may be increasing in prevalence. Beginning in 2008, the National Institute of
Allergy and Infectious Diseases, working with other organizations and advocacy groups, led the development of the
first clinical guidelines for the diagnosis and management of food allergy. A recent landmark clinical trial and other
emerging data suggest that peanut allergy can be prevented through introduction of peanut-containing foods
beginning in infancy.
Objectives: Prompted by these findings, along with 25 professional organizations, federal agencies, and patient
advocacy groups, the National Institute of Allergy and Infectious Diseases facilitated development of addendum
guidelines to specifically address the prevention of peanut allergy.
Results: The addendum provides 3 separate guidelines for infants at various risk levels for the development
of peanut allergy and is intended for use by a wide variety of health care providers. Topics addressed include
the definition of risk categories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral
food challenges), and the timing and approaches for introduction of peanut-containing foods in the health
care provider’s office or at home. The addendum guidelines provide the background, rationale, and strength
of evidence for each recommendation.
Conclusions: Guidelines have been developed for early introduction of peanut-containing foods into the
diets of infants at various risk levels for peanut allergy.
Keywords: Food, Peanut, Allergy, Prevention, Guidelines
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Introduction
Peanut allergy is a growing public health problem. In
1999, peanut allergy was estimated to affect 0.4% of chil-
dren and 0.7% of adults in the United States [1], and by
2010, peanut allergy prevalence had increased to ap-
proximately 2% among children in a national survey [2],
with similar results reported in a regional cohort. [3]
Peanut allergy is the leading cause of death related to
food-induced anaphylaxis in the United States [4, 5], and
although overall mortality is low, the fear of life-
threatening anaphylactic reactions contributes signifi-
cantly to the medical and psychosocial burden of
disease. In the majority of patients, peanut allergy begins
early in life and persists as a lifelong problem. Therefore,
cost-effective measures to prevent peanut allergy would
have a high effect in terms of improving public health,
reducing personal suffering, and decreasing health care
use and costs.
The “Guidelines for the diagnosis and management of
food allergy in the United States” [6] were published in
December 2010 by an Expert Panel and a Coordinating
Committee convened by the National Institute of Allergy
and Infectious Diseases (NIAID). These guidelines did
not offer strategies for the prevention of food allergy and
particularly peanut allergy because of a lack of definitive
studies at the time. The guidelines indicated that “insuf-
ficient evidence exists for delaying introduction of solid
foods, including potentially allergenic foods, beyond 4
to 6 months of age, even in infants at risk of devel-
oping allergic disease.” This statement differed from
previous clinical practice guidelines in the United
Kingdom [7] and United States [8], which recom-
mended the exclusion of allergenic foods from the di-
ets of infants at high risk for allergy and is consistent
with more recent recommendations regarding primary
allergy prevention [9–12].
In February 2015, the New England Journal of
Medicine published the results of the Learning Early
about Peanut Allergy (LEAP) trial [13]. This trial was
based on a prior observation [14] that the prevalence of
peanut allergy was 10-fold higher among Jewish children
in the United Kingdom compared with Israeli children
of similar ancestry. In Israel, peanut-containing foods
are usually introduced in the diet when infants are ap-
proximately 7 months of age and consumed in substan-
tial amounts, whereas in the United Kingdom children
do not typically consume any peanut-containing foods
during their first year of life. The LEAP trial randomized
640 children between 4 and 11 months of age with se-
vere eczema, egg allergy, or both to consume or avoid
peanut-containing foods until 60 months of age, at
which time a peanut oral food challenge (OFC) was con-
ducted to determine the prevalence of peanut allergy.
LEAP trial participants were stratified at study entry into
2 separate study cohorts on the basis of pre-existing
sensitization to peanut, as determined by means of skin
prick testing: one cohort consisted of infants with no
measureable skin test wheal to peanut (negative skin test
response) and the other consisted of those with measur-
able wheal responses (1–4 mm in diameter). Infants with
a 5 mm wheal diameter or greater were not randomized
because the majority of infants at this level of
sensitization were presumed to be allergic to peanut.
Among the 530 participants in the intention-to-treat
population with negative baseline skin test response to
peanut, the prevalence of peanut allergy at 60 months of
age was 13.7% in the peanut avoidance group and 1.9%
in the peanut consumption group (P < .001; an 86.1%
relative reduction in the prevalence of peanut allergy).
Among the 98 participants with a measurable peanut
skin test response at entry, the prevalence of peanut al-
lergy was 35.3% in the avoidance group and 10.6% in the
consumption group (P = .004; a 70% relative reduction in
the prevalence of peanut allergy).
The LEAP trial was the first randomized trial to
study early allergen introduction as a preventive strat-
egy. Because of the size of the observed effect and
the large number of study participants, its outcome
received wide publicity in both the medical commu-
nity and the press. This raised the need to
operationalize the LEAP findings by developing clin-
ical recommendations focusing on peanut allergy
prevention. To achieve this goal and its wide imple-
mentation, the NIAID invited the members of the
2010 Guidelines Coordinating Committee and other
stakeholder organizations to develop this addendum
on peanut allergy prevention to the 2010 “Guidelines
for the diagnosis and management of food allergy in
the United States.” Twenty-six stakeholder organiza-
tions participated in this 2015–2016 Coordinating
Committee. Of note, unrelated to this effort, a con-
sensus statement on behalf of 9 international profes-
sional societies regarding the implications and
implementation of the LEAP trial findings was pub-
lished as well [15].
Additional evidence on early introduction of allergenic
foods comes from the LEAP-On study [16], which dem-
onstrated the durability of oral tolerance to peanut
achieved in the LEAP trial and the Enquiring About
Tolerance study [17], which assessed the potential bene-
fits of early introduction of 6 allergenic foods in a non–
high-risk cohort.
Development of the 2017 addendum to the 2010
“Guidelines for the diagnosis and management of
food allergy”
The process to develop the 2017 addendum closely
followed that used in the 2010 guidelines [6].
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Coordinating Committee
The NIAID established a Coordinating Committee (CC),
the members of which are listed in Appendix A, to over-
see the development of the addendum; review drafts of
the addendum for accuracy, practicality, clarity, and broad
utility of the recommendations in clinical practice; review
and approve the final addendum; and disseminate the ad-
dendum. The CC members represented 26 professional
organizations, advocacy groups, and federal agencies.
Expert Panel
The CC convened an Expert Panel (EP) in June 2015
that was chaired by Joshua Boyce, MD. The 26 panel
members, listed in Appendix B, were specialists from a
variety of relevant clinical, scientific, and public health
areas. Panel members were nominated by the CC orga-
nizations, and the composition of the panel received
unanimous approval by the CC member organizations.
The charge to the EP was to use the literature review
prepared by the NIAID (see the next section) in con-
junction with consensus expert opinion and EP-
identified supplementary documents to (1) develop
evidence-based recommendations for the early introduc-
tion of dietary peanut to prevent peanut allergy; (2)
agree on principles for grading the evidence; (3) achieve
consensus while allowing ample opportunity for consid-
eration of divergent opinions; (4) determine whether the
recommendations could extend beyond peanut to other
food allergens; and (5) keep patient and societal interests
at the forefront. The new recommendations are intended
to supplement and modify guidelines 37 to 40 in Section
5.3.4 of the 2010 guidelines: “Prevention of food allergy.”
Literature review
NIAID staff conducted a literature search of PubMed lim-
ited to the years 2010 (January) to 2016 (June). Using the
following specific search terms ([food allergy or milk allergy
or egg allergy or peanut allergy] OR [eczema or atopic
dermatitis] AND prevention), PubMed returned more than
1500 articles. NIAID staff reviewed 1506 abstracts and
assessed each for relevance to the topic of food allergy pre-
vention with an emphasis on peanut allergy. Sixty-four pub-
lications (original research articles, editorials/letters, and
systematic reviews) were deemed relevant and placed into 2
tiers: tier 1 contained 18 items considered highly relevant
to the early introduction of peanut or other allergenic foods
(see Appendix C), and tier 2 contained 46 items on related
topics, such as food allergy or eczema prevention.
Assessing the quality of the body of evidence
For each of the 18 tier 1 references, the EP assessed quality
by using the Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) approach [18]. GRADE
provides a comprehensive and transparent methodology to
develop recommendations for the diagnosis, treatment, and
management of patients. In assessing the body of evidence
of a group of relevant articles or of a single article, GRADE
considers study design and other factors, such as the preci-
sion, consistency, and directness of the data. By using this
approach, GRADE then provides a categorical assessment
of the contribution of individual publications and the overall
quality and strength of the body of evidence.
Each publication was assigned a grade according to
the following criteria [19, 20]:
 High: Further research is very unlikely to have an
effect on the quality of the body of evidence, and
therefore the confidence in the recommendation is
high and unlikely to change.
 Moderate: Further research is likely to have an
effect on the quality of the body of evidence and
may change the recommendation.
 Low: Further research is very likely to have an
important effect on the body of evidence and is
likely to change the recommendation.
A GRADE designation of “low” for the quality of evidence
does not imply that an article is not factually correct or
lacks scientific merit. For example, a well-designed and exe-
cuted single-site study of a treatment in a small cohort of
highly selected subjects may still yield an overall GRADE
rating of “low.” This is because such a study is characterized
as providing “sparse” data, and the patient population may
not be representative of the at-risk population. Each of these
factors reduces the level of evidence from “high,” which is
the initial designation for evidence from randomized con-
trolled trials. It is worth emphasizing that these 2 limitations
are not of the study per se but of the body of evidence.
Preparation of the draft addendum
The draft version of the addendum, prepared by the NIAID,
contained 3 new guidelines and was reviewed, modified,
and endorsed by the EP members. The EP-approved docu-
ment was forwarded to the CC members for review.
Public comment period, addendum revision, and final
approval
Concurrent with CC member review, the draft addendum
was posted to the NIAID Web site in March 2016 for a
period of 45 days to allow for public review and comment.
One hundred four comments were received. All comments
were reviewed by the EP and the CC, and some contrib-
uted to the final revision of the addendum. The final ad-
dendum was reviewed and approved by the EP and the CC.
Dissemination of the addendum guidelines
The final addendum is published herein and available
through the Internet.
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Defining the strength of each clinical guideline
The EP has used the verb “recommends” or “suggests”
for each clinical recommendation.
These words convey the strength of the recommenda-
tion, defined as follows:
 Recommend is used when the EP strongly
recommended for or against a particular course of
action.
 Suggest is used when the EP weakly recommended
for or against a particular course of action.
Addendum guidelines
Table 1 provides a summary of the 3 addendum guide-
lines to be used as a quick reference.
The EP came to consensus on the following 3 defini-
tions used throughout the addendum guidelines.
 Severe eczema is defined as persistent or frequently
recurring eczema with typical morphology and
distribution assessed as severe by a health care
provider and requiring frequent need for
prescription-strength topical corticosteroids,
calcineurin inhibitors, or other anti-inflammatory
agents despite appropriate use of emollients.
 Egg allergy is defined as a history of an allergic
reaction to egg and a skin prick test (SPT) wheal
diameter of 3 mm or greater with egg white extract,
or a positive oral egg food challenge result.
 A specialist is defined as a health care provider with
the training and experience to (1) perform and
interpret SPTs and OFCs and (2) know and manage
their risks. Such persons must have appropriate
medications and equipment on site.
Addendum guideline 1
The EP recommends that infants with severe eczema, egg
allergy, or both have introduction of age-appropriate
peanut-containing food as early as 4 to 6 months of age to
reduce the risk of peanut allergy. Other solid foods should
be introduced before peanut-containing foods to show
that the infant is developmentally ready. The EP recom-
mends that evaluation with peanut-specific IgE (peanut
sIgE) measurement, SPTs, or both be strongly considered
before introduction of peanut to determine if peanut
should be introduced and, if so, the preferred method of
introduction. To minimize a delay in peanut introduction
for children who may test negative, testing for peanut sIgE
may be the preferred initial approach in certain health care
settings, such as family medicine, pediatrics, or dermatol-
ogy practices, in which skin prick testing is not routine.
Alternatively, referral for assessment by a specialist may
be an option if desired by the health care provider and
when available in a timely manner.
Figure 1 provides recommended approaches for evalu-
ation of children with severe eczema, egg allergy, or both
before peanut introduction.
A peanut sIgE level of less than 0.35 kUA/L has strong
negative predictive value for the diagnosis of peanut al-
lergy [21]. Therefore, peanut sIgE testing may help in
certain health care settings (eg, family medicine,
pediatric, or dermatology practices, where skin prick
testing is not routine) to reduce unnecessary referrals of
children with severe eczema, egg allergy, or both and to
minimize a delay in peanut introduction for children
who may have negative test results. However, the EP em-
phasizes that a peanut sIgE level of 0.35 kUA/L or
greater lacks adequate positive predictive value for the
diagnosis of peanut allergy, and an infant with a value of
0.35 kUA/L or greater should be referred to a specialist.
Thus, peanut sIgE testing can place an infant into one
of 2 categories (Fig. 1):
 sIgE Category A: If the peanut sIgE level is less than
0.35 kUA/L (ImmunoCAP), the EP recommends that
peanut should be introduced in the diet soon
thereafter, with a cumulative first dose of
approximately 2 g of peanut protein given in this
feeding. This can be given as a feeding at home
(Appendix D), considering the low likelihood of a
severe allergic reaction. If the caregiver or health
care provider has concerns, a supervised feeding can
be offered at the health care provider’s office
(Appendix E).
 sIgE Category B: If the peanut sIgE level is 0.35
kUA/L or greater (ImmunoCAP), the EP recommends
that the child be referred to a specialist for further
consultation and possible skin prick testing.
Table 1 Summary of addendum guidelines 1, 2, and 3
Addendum guideline Infant criteria Recommendations Earliest age of peanut introduction
1 Severe eczema, egg allergy, or
both
Strongly consider evaluation by sIgE
measurement and/or SPT and, if
necessary, an OFC. Based on test results,
introduce peanut-containing foods.
4–6 months
2 Mild-to-moderate eczema Introduce peanut-containing foods Around 6 months
3 No eczema or any food allergy Introduce peanut-containing foods Age appropriate and in accordance with
family preferences and cultural practices
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The EP does not recommend food allergen panel
testing or the addition of sIgE testing for foods other
than peanut because of their poor positive predictive
value, which could lead to misinterpretation, overdiag-
nosis of food allergy, and unnecessary dietary restric-
tions [6].
SPTs with peanut extract can place an infant in one of
3 categories (Fig. 1):
 SPT Category A: If an SPT to peanut extract
produces a wheal diameter of 2 mm or less above
saline control, the EP recommends that peanut be
introduced in the diet soon after testing, with a
cumulative first dose of approximately 2 g of peanut
protein given in this feeding. This can be given at
home (Appendix D), considering the low likelihood
of a severe allergic reaction. If the caregiver or
health care provider has concerns, a supervised
feeding can be offered at the health care provider’s
office (Appendix E).
 SPT Category B: If an SPT to peanut extract
produces a wheal diameter of 3 to 7 mm greater
than that elicited by the saline control, the EP
suggests that a supervised peanut feeding or a
graded OFC be undertaken at a specialist’s office or
a specialized facility (see Appendices E and G,
respectively). Infants in this category can be
sensitized without being allergic to peanut and
might benefit from early peanut consumption. If the
supervised peanut feeding or graded OFC yields no
reaction, the EP recommends that peanut should be
added to the child’s diet. If the supervised peanut
feeding or the graded OFC results in an allergic
reaction, the EP recommends that the child
should strictly avoid dietary peanut and the family
should be counseled regarding food allergy
management.
 SPT Category C: If an SPT produces a wheal
diameter 8 mm or greater than that elicited by
the saline control, the likelihood of peanut
allergy is high. Children in this category should
continue to be evaluated and managed by a
specialist. [21–23]
Fig. 1 Recommended approaches for evaluation of children with severe eczema and/or egg allergy before peanut introduction. *To minimize a
delay in peanut introduction for children who may test negative, testing for peanut-specific Ige may be the preferred initial approach in certain
health care settings. Food allergen panel testing or the addition of sIgE testing for foods other than peanut is not recommended due to poor
positive predictive value
Box 1 Important considerations for skin prick testing
SPT reagents, testing devices, and methodology can differ
significantly among health care providers in the United States or
elsewhere [22]. The EP recommends that specialists adjust their
SPT categorization criteria according to their own training and
experience.
Health care providers conducting OFCs in infants with 3 mm or
greater SPT responses should be aware that the probability of a
positive challenge response increases with wheal size. These
data come from the HealthNuts Study in children 12 to
18 months of age; of note, the severity of these reactions was
relatively mild [21, 23].
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How much dietary peanut protein to introduce
If the decision is made to introduce dietary peanut based
on the recommendations of addendum guideline 1, the
total amount of peanut protein to be regularly consumed
per week should be approximately 6 to 7 g over 3 or
more feedings (see Appendix F). In the LEAP trial, at
evaluations conducted at 12 and 30 months of age, 75%
of children in the peanut consumption group reported
eating at least this amount of peanut, based on analysis
of a 3-day food diary recorded just before the evaluation.
Rationale
Infants with severe eczema, egg allergy, or both are at high
risk for the development of peanut allergy. Significant evi-
dence on this group is available from the infants who partici-
pated in the LEAP trial or were screened for the LEAP trial
but were not enrolled because of a large SPT response
(>4 mm). At 60 months of age, approximately 23% of peanut
avoiders and those infants not enrolled had food allergy [24].
Balance of benefits and harms
In the LEAP trial, among the 530 participants in the
intention-to-treat population with negative baseline SPT
responses to peanut, 13.7% of the avoidance group and
1.9% of the consumption group had peanut allergy at
60 months of age (P < .001; a 12.6% absolute risk reduc-
tion and an 86.1% relative risk reduction in the prevalence
of peanut allergy, resulting in a number needed to treat of
8.5 [number of infants needed to have early introduction
of peanut to prevent peanut allergy in one child]). Among
the 98 participants with positive peanut SPT responses at
entry, 35.3% of the avoidance group and 10.6% of the con-
sumption group had peanut allergy at 60 months of age
(P = .004; a 24.7% absolute risk reduction and a 70% rela-
tive risk reduction in the prevalence of peanut allergy,
resulting in a number needed to treat of 4).
The LEAP-On study [24] demonstrated that the benefits
achieved in the LEAP trial persisted when LEAP trial pea-
nut consumers subsequently avoided peanut for 1 year
from 60 to 72 months of age. This indicates that the oral
tolerance achieved in the LEAP trial was durable.
The LEAP trial did not include infants with SPT
wheals greater than 4 mm, and therefore no data are
available on the potential effectiveness of peanut con-
sumption in preventing peanut allergy in this group.
However, EP members believe it is possible that some of
these infants may benefit from early introduction of pea-
nut provided that they tolerate oral peanut.
As shown in Fig. 1, the EP recommends that infants
with severe eczema, egg allergy, or both, with peanut
sIgE levels of less than 0.35 kUA/L or with a peanut SPT
wheal of 2 mm or less have dietary peanut introduced as
early as 4 to 6 months of age without a need for further
evaluation. This recommendation is supported by expert
opinion and analysis of the LEAP population findings. In
the LEAP trial, infants consuming peanut in this post
hoc defined category had a relative risk reduction of 79%
of having peanut allergy at 60 months of age compared
with infants who avoided peanut.
In the LEAP trial, at study entry, all infants randomly
assigned to the consuming group had a baseline peanut
OFC. Of the 272 infants with no wheal induced by peanut
SPT and who received a baseline oral peanut challenge,
only 1 had a reaction presenting as an erythematous urti-
carial rash that was graded as a “moderate” adverse event
and was treated successfully with chlorpheniramine.
Among the 29 infants with a wheal diameter of 1 to 2 mm
who received a baseline oral peanut challenge, 2 had reac-
tions, which also presented with mild symptoms not re-
quiring treatment with epinephrine. Therefore, for the
SPT Category A children, the risk of a severe reaction to
peanut at first introduction is low, and introduction of
peanut at home is an option. However, it is understand-
able that some caregivers of infants with severe eczema,
egg allergy, or both may be uncomfortable introducing
dietary peanut at home. In such cases the health care pro-
vider should offer the option of a supervised feeding of a
peanut-containing food in the office.
The rate of positive peanut OFC results at baseline for in-
fants with a 3 to 4 mm wheal diameter (4/17 infants) was
higher than in infants with 0 to 2 mm wheal diameters (3/
301 infants), but the elicited symptoms were mild. Infants
with larger wheal diameters (>4 mm) were not included in
the LEAP trial, and therefore no safety data are available
from this group. However, based on the Australian Health-
Nuts study, which conducted peanut OFCs in a large num-
ber of older (12–18 months old) children from the general
Australian population, the rate of reactions to peanut is ex-
pected to be substantially higher with increasing SPT wheal
diameter [21, 23]. In the HealthNuts study [23] an SPT
wheal diameter of 8 mm or greater had a 95% positive pre-
dictive value for peanut allergy (positive oral peanut chal-
lenge result). Therefore, the EP recommends that for SPT
Category B infants (3 to 7 mm SPT wheal diameter), a su-
pervised feeding or a graded peanut OFC should be con-
ducted in a specialist’s office or a specialized facility
(Appendix G). SPT Category C infants are considered high
risk for established allergy to peanut and should not receive
peanut-containing foods in their diet, unless such foods are
recommended by a specialist after further evaluation.
Quality of evidence: Moderate
The designation of the quality of evidence as “moderate”
(as opposed to “high”) is based on the fact that this recom-
mendation derives primarily from a single randomized,
open-label study: the LEAP trial. However, it should be
noted that the assessment of the LEAP trial’s primary out-
come was based on a double-blind, placebo-controlled
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OFC. Furthermore, confidence in this recommendation is
bolstered by the large effect size demonstrated in the LEAP
trial and prior epidemiologic data that peanut allergy is
relatively infrequent in Israel, where early childhood con-
sumption of peanut is common.
Contribution of expert opinion
Significant.
Additional comments
1. Breast-feeding recommendations: The EP recognizes
that early introduction of peanut may seem to depart
from recommendations for exclusive breast-feeding
through 6 months of age [25, 26]. However, it should
be noted that data from the nutrition analysis of the
LEAP cohort [27] indicate that introduction of peanut
did not affect the duration or frequency of breast-
feeding and did not influence growth or nutrition.
2. Age of peanut introduction: For children with severe
eczema, egg allergy, or both, the EP recommends
that introduction of solid foods begins at 4 to
6 months of age, starting with solid food other than
peanut, so that the child can demonstrate the ability
to consume solid food without evidence of
nonspecific signs and symptoms that could be
confused with IgE-mediated food allergy. However, it
is important to note that infants in the LEAP trial
were enrolled between 4 and 11 months of age and
benefitted from peanut consumption regardless of
age at entry. Therefore, if the 4- to 6-month time
window is missed for any reason, including
developmental delay, infants may still benefit from
early peanut introduction. On the other hand, older
age at screening is associated with larger wheal
diameters induced by peanut SPT and hence a
higher likelihood of established peanut allergy [28].
A practical consideration for applying this guideline
at 4 to 6 months of age is that infants visit their
health care provider for well-child evaluations and
infant immunizations at this time. This provides a
fortuitous opportunity for eczema evaluation,
caregiver reporting of egg allergy, and, if needed,
referral to a specialist for peanut allergy evaluation
before dietary introduction of peanut.
3. Considerations for family members with established
peanut allergy: The EP recognizes that many infants
eligible for early peanut introduction under this
guideline will have older siblings or caregivers with
established peanut allergy. The EP recommends that
in this situation caregivers discuss with their health
care providers the overall benefit (reduced risk of
peanut allergy in the infant) versus risk (potential for
further sensitization and accidental exposure of the
family member to peanut) of adding peanut to the
infant’s diet.
4. Children identified as allergic to peanut: For children
who have been identified as allergic to peanut, the
EP recommends strict peanut avoidance. This may
include those children in SPT Category B who fail
the supervised peanut feeding or the OFC, or those
children in SPT Category C who, on further
evaluation by a specialist, are confirmed as being
allergic to peanut. These children should be under
long-term management by a specialist.
Addendum guideline 2
The EP suggests that infants with mild-to-moderate eczema
should have introduction of age-appropriate peanut-
containing food around 6 months of age, in accordance with
family preferences and cultural practices, to reduce the risk
of peanut allergy. Other solid foods should be introduced
before peanut-containing foods to show that the infant is de-
velopmentally ready. The EP recommends that infants in
this category may have dietary peanut introduced at home
without an in-office evaluation. However, the EP recognizes
that some caregivers and health care providers may desire
an in-office supervised feeding, evaluation, or both.
Rationale
The LEAP trial did not target infants with mild or moderate
eczema. The EP considered the potential risk/benefit ratio of
early dietary peanut introduction in infants with mild-to-
moderate eczema and concluded that the individual and so-
cietal benefits of introducing peanut in this population
would be significant. The EP has no reason to believe that
the mechanisms of protection of early dietary peanut differ
in infants with mild-to-moderate eczema from those that
lead to protection in infants at higher risk of peanut allergy.
Balance of benefits and harms
The LEAP trial included only infants with severe eczema
or egg allergy based on careful medical history. Therefore,
some infants who participated in the LEAP trial based on
the presence of egg allergy had atopic dermatitis severity
scores (SCORAD scores [29]) at screening that would
have placed them in the moderate or mild eczema cat-
egory. The EP considered the outcomes of these children
and concluded that infants with mild-to-moderate eczema
would likely benefit from early peanut introduction.
Quality of evidence
Low.
The quality of evidence is low because this recommenda-
tion is based on extrapolation of data from a single study.
Contribution of expert opinion
Significant.
Togias et al. World Allergy Organization Journal  (2017) 10:1 Page 7 of 18
Additional comment
Additional support for early introduction of peanut in
infants who do not have severe eczema comes from the
Enquiring About Tolerance study [17], which enrolled
infants from the general population at 3 months of age
and sequentially introduced 6 allergenic foods beginning
at the time of enrollment. These children were not
intentionally selected based on increased risk of food al-
lergy or atopy. Although the intention-to-treat group did
not show benefit, most likely because of relatively poor
compliance with feeding recommendations, the children
in the per-protocol group who had peanut introduced
early in infancy showed a significant reduction in peanut
sensitization and peanut allergy at age 3 years. This
study also provides support for guideline 3 below.
Addendum guideline 3
The EP suggests that infants without eczema or any food al-
lergy have age-appropriate peanut-containing foods freely
introduced in the diet together with other solid foods and in
accordance with family preferences and cultural practices.
Rationale
No evidence exists for restricting allergenic foods in in-
fants without known risks for food allergy. The probability
for development of peanut allergy in such children is very
low. However, approximately 14% of all children with pea-
nut allergy at age 12 to 18 months in the HealthNuts
Study lacked known risk factors for food allergy [16]. Con-
sequently, because such children constitute a significant
majority of any birth cohort, they contribute substantially
to the overall societal burden of peanut allergy. The EP
finds no evidence to suggest that mechanisms of oral tol-
erance induction would differ in these infants from the
immunologic mechanisms that are protective in infants at
higher risk of peanut allergy. Thus, the early introduction
of dietary peanut in children without risk factors for pea-
nut allergy is generally anticipated to be safe and to con-
tribute modestly to an overall reduction in the prevalence
of peanut allergy. Furthermore, in countries such as Israel,
where peanut products are a popular component of the
diet and where they are introduced early in life, the preva-
lence of peanut allergy is low [14].
Balance of benefits and harms
The EP acknowledges that any analysis of benefit and
harm in this population relies primarily on expert opinion
and is subject to current differences in regional/societal
rates of peanut consumption and peanut sensitization. In
countries where peanut products are not widely con-
sumed by adults, early dietary introduction of peanut
could lead to an increase in sensitization and allergic man-
ifestations. Hence the EP cautions that this guideline be
implemented in the context of societal routines/norms.
Quality of evidence
Low.
Contribution of expert opinion
Significant.
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Box 2 Clinical implications
These guidelines will help health care providers with early
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of infants.
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Appendix D
Instructions for home feeding of peanut protein for
infants at low risk of an allergic reaction to peanut
These instructions for home feeding of peanut protein
are provided by your doctor. You should discuss any
questions that you have with your doctor before starting.
These instructions are meant for feeding infants who
have severe eczema or egg allergy and were allergy
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tested (blood test, skin test, or both) with results that
your doctor considers safe for you to introduce peanut
protein at home (low risk of allergy).
General instructions
1. Feed your infant only when he or she is healthy; do
not do the feeding if he or she has a cold, vomiting,
diarrhea, or other illness.
2. Give the first peanut feeding at home and not at a
day care facility or restaurant.
3. Make sure at least 1 adult will be able to focus all
of his or her attention on the infant, without
distractions from other children or household
activities.
4. Make sure that you will be able to spend at least
2 h with your infant after the feeding to watch for
any signs of an allergic reaction.
Feeding your infant
1. Prepare a full portion of one of the peanut-
containing foods from the recipe options below.
2. Offer your infant a small part of the peanut serving
on the tip of a spoon.
3. Wait 10 min.
4. If there is no allergic reaction after this small
taste, then slowly give the remainder of the
peanut-containing food at the infant’s usual eating
speed.
What are symptoms of an allergic reaction? What should I
look for?
 Mild symptoms can include:
○ a new rash
or
○ a few hives around the mouth or face
 More severe symptoms can include any of the
following alone or in combination:
○ lip swelling
○ vomiting
○ widespread hives (welts) over the body
○ face or tongue swelling
○ any difficulty breathing
○ wheeze
○ repetitive coughing
○ change in skin color (pale, blue)
○ sudden tiredness/lethargy/seeming limp
If you have any concerns about your infant’s re-
sponse to peanut, seek immediate medical attention/
call 911.
Four recipe options, each containing approximately 2 g
of peanut protein
Note: Teaspoons and tablespoons are US measures (5
and 15 mL for a level teaspoon or tablespoon,
respectively).
Option 1: Bamba (Osem, Israel), 21 pieces (approximately
2 g of peanut protein)
Note: Bamba is named because it was the product
used in the LEAP trial and therefore has proven
efficacy and safety. Other peanut puff products
with similar peanut protein content can be
substituted.
a. For infants less than 7 months of age, soften the
Bamba with 4 to 6 teaspoons of water.
b. For older infants who can manage dissolvable
textures, unmodified Bamba can be fed. If
dissolvable textures are not yet part of the
infant’s diet, softened Bamba should be
provided.
Option 2: Thinned smooth peanut butter, 2 teaspoons
(9–10 g of peanut butter; approximately 2 g of peanut
protein)
a. Measure 2 teaspoons of peanut butter and slowly
add 2 to 3 teaspoons of hot water.
b. Stir until peanut butter is dissolved, thinned, and
well blended.
c. Let cool.
d. Increase water amount if necessary (or add previously
tolerated infant cereal) to achieve consistency
comfortable for the infant.
Option 3: Smooth peanut butter puree, 2 teaspoons
(9–10 g of peanut butter; approximately 2 g of peanut
protein)
a. Measure 2 teaspoons of peanut butter.
b. Add 2 to 3 tablespoons of pureed tolerated fruit or
vegetables to peanut butter. You can increase or
reduce volume of puree to achieve desired
consistency.
Option 4: Peanut flour and peanut butter powder, 2
teaspoons (4 g of peanut flour or 4 g of peanut
butter powder; approximately 2 g of peanut
protein)
Note: Peanut flour and peanut butter powder are
2 distinct products that can be interchanged be-
cause they have a very similar peanut protein
content.
a. Measure 2 teaspoons of peanut flour or peanut
butter powder.
b. Add approximately 2 tablespoons (6–7
teaspoons) of pureed tolerated fruit or
vegetables to flour or powder. You can increase
or reduce volume of puree to achieve desired
consistency.
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Appendix E
For health care providers: In-office supervised feeding
protocol using 2 g of peanut protein
General instructions
1. These recommendations are reserved for an infant
defined in guideline 1 as one with severe eczema, egg
allergy, or both and with negative or minimally
reactive (1 to 2 mm) SPT responses and/or peanut
sIgE levels of less than 0.35 kUA/L. They also may
apply to the infant with a 3 to 7 mm SPT response if
the specialist health care provider decides to conduct
a supervised feeding in the office (as opposed to a
graded OFC in a specialized facility [see Fig. 1]).
These recommendations can also be followed for in-
fants with mild-to-moderate eczema, as defined in
guideline 2, when caregivers and health care providers
may desire an in-office supervised feeding.
2. Proceed only if the infant shows no evidence of any
concomitant illness, such as an upper respiratory
tract infection.
a. Start with a small portion of the initial peanut
serving, such as the tip of a teaspoon of peanut
butter puree/softened Bamba.
b. Wait 10 min; if there is no sign of reaction after
this small portion is given, continue gradually
feeding the remaining serving of peanut-
containing food (see options below) at the in-
fant’s typical feeding pace.
c. Observe the infant for 30 min after 2 g of peanut
protein ingestion for signs/symptoms of an
allergic reaction.
Four recipe options, each containing approximately 2 g of
peanut protein
Note: Teaspoons and tablespoons are US measures (5 and
15 mL for a level teaspoon or tablespoon, respectively).
Option 1: Bamba (Osem, Israel), 21 pieces (approximately
2 g of peanut protein)
Note: Bamba is named because it was the product used
in the LEAP trial and therefore has known peanut pro-
tein content and proven efficacy and safety. Other pea-
nut puffs products with similar peanut protein content
can be substituted for Bamba.
a. For infants less than 7 months of age, soften the
Bamba with 4 to 6 teaspoons of water.
b. For older infants who can manage dissolvable
textures, unmodified Bamba can be fed. If
dissolvable textures are not yet part of the infant’s
diet, softened Bamba should be provided.
Option 2: Thinned smooth peanut butter, 2 teaspoons
(9–10 g of peanut butter; approximately 2 g of peanut
protein)
a. Measure 2 teaspoons of peanut butter and slowly
add 2 to 3 teaspoons hot water.
b. Stir until peanut butter is dissolved and thinned
and well blended.
c. Let cool.
d. Increase water amount if necessary (or add
previously tolerated infant cereal) to achieve
consistency comfortable for the infant.
Option 3: Smooth peanut butter puree, 2 teaspoons
(9–10 g of peanut butter; approximately 2 g of peanut
protein)
a. Measure 2 teaspoons of peanut butter.
b. Add 2 to 3 tablespoons of previously tolerated
pureed fruit or vegetables to peanut butter. You can
increase or reduce volume of puree to achieve
desired consistency.
Option 4: Peanut flour and peanut butter powder, 2
teaspoons (4 g of peanut flour or 4 g of peanut butter
powder; approximately 2 g of peanut protein)
Note: Peanut flour and peanut butter powder are 2 dis-
tinct products that can be interchanged because they
have, on average, a similar peanut protein content.
a. Measure 2 teaspoons of peanut flour or peanut
butter powder.
b. Add approximately 2 tablespoons (6–7 teaspoons)
of pureed tolerated fruit or vegetables to flour or
powder. You can increase or reduce the volume of
puree to achieve desired consistency.
Appendix F
Peanut protein in peanut-containing foods
If the decision is made to introduce dietary peanut to
the infant’s diet, the total amount of peanut protein to
be regularly consumed per week should be approxi-
mately 6 to 7 g over 3 or more feedings. In the LEAP
trial, at evaluations conducted at 12 and 24 months of
age, 75% of children in the peanut consumption group
reported eating at least this amount of peanut.
Be aware of choking risks
 Whole nuts should not be given to children less
than 5 years of age.
 Peanut butter directly from a spoon or in lumps/
dollops should not be given to children less than
4 years of age.
If, after a week or more eating peanut, your infant or
child displays mild allergic symptoms within 2 h of eat-
ing peanut, you should contact your health care
provider.
Typical peanut-containing foods, their peanut protein
content, and feeding tips for infants are provided in
Table 2, and their nutritional content is found in Table 3.
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Appendix G
Graded OFC protocol
From “Conducting an oral food challenge to peanut in
an infant: a work group report.” [30]
General instructions
1. A graded OFC should be performed only by a
specialist with the training and experience to (1)
perform and interpret skin prick testing and OFCs
and (2) know and manage their risks. Such persons
must have appropriate medications and equipment
on site.
2. Four peanut preparations are provided:
a. Option 1: Smooth peanut butter mixed with
either a previously tolerated pureed fruit or
vegetable.
b. Option 2: Smooth peanut butter dissolved
carefully with hot water and cooled.
c. Option 3: Peanut flour mixed with either a
previously tolerated pureed fruit or vegetable.
Peanut butter powder can be used instead of the
peanut flour.
d. Option 4: Bamba peanut snack dissolved in hot
water and cooled or even as a solid (ie, as a
stick).
Note: Bamba (Osem, Israel) is named because it was
the product used in the LEAP trial and therefore has
known peanut protein content and proven efficacy and
safety. Other peanut puff products with similar peanut
protein content can be substituted for Bamba.
3. The peanut protein content of the graded OFC
protocol is identical for all peanut preparations
provided below, except that the volume of food
ingested per dose is different. The protocol consists of
5 incremental doses, given 15 to 20 min apart, with a
cumulative peanut protein total of approximately 4 g
per the 3.9 g total in the LEAP trial.
4. Refer to Table 4 and direct parents to discontinue
specific medications for the prescribed amount of
time before the graded OFC. Note that certain
medications are allowed.
Be prepared in case of a severe reaction (see Table 5)
Note: Teaspoons and tablespoons are US measures (5
and 15 mL for a level teaspoon or tablespoon, respectively).
Table 2 Typical peanut-containing foods, their peanut protein content, and feeding tips for infants
Bamba Peanut butter Peanuts Peanut flour or peanut
butter powder
Amount containing
approximately
2 g of peanut protein
17 g or 2 3= of a 28-g (1-oz)
bag or 21 sticks
9–10 g or 2 teaspoons 8 g or ~ 10 whole peanuts
(21 2= teaspoons of
grounded peanuts)
4 g or 2 teaspoons
Typical serving size 1 bag (28 g) Spread on a slice of bread
or toast (16 g)
21 2= teaspoons of ground
peanuts (8 g)
No typical serving size
Peanut protein per
typical serving
3.2 g 3.4 g 2.1 g No typical serving size
Feeding tips For a smooth texture, mix with
warm water (then let cool) or
breast milk or infant formula
and mash well. Pureed or
mashed fruit or vegetables
can be added. Older children
can be offered sticks of Bamba.
For a smooth texture, mix with
warm water (then let cool) or
breast milk or infant formula.
For older children, mix with
pureed or mashed fruit or
vegetables or any suitable
family foods, such as yogurt
or mashed potatoes.
Use blender to create a
powder or paste. 2–21 2=
teaspoons of ground
peanuts can be added to
a portion of yogurt or
pureed fruit or savory meal.
Mix with yogurt or
apple sauce.
Notes: Bamba (Osem, Israel) is named because it was the product used in the LEAP trial and therefore has known peanut protein content and proven efficacy and
safety. Other peanut puff products with similar peanut protein content can be substituted for Bamba
Teaspoons and tablespoons are US measures (5 and 15 mL for a level teaspoon or tablespoon, respectively)
Table 3 Nutritional content of peanut-containing foods
Per approximately 2 g of peanut protein Bambaa (17 g) Peanut butter (10 g) Peanuts (8 g) Peanut butter powder (4 g) Peanut flour (4 g)
kcal 93 59 45 15 13
Sugar (g) 0.4 0.65 0.38 0.4 0.33
Salt (mg) 68 48 1 31 7
Fat (g) 6.1 4.95 3.94 0.49 0.02
aThe nutritional content of peanut puff products (other than Bamba) can be obtained from their manufacturers
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Option 1: Measures for smooth peanut butter puree
Option 2: Measures for smooth thinned peanut butter
Dose Peanut butter volumea Equivalent weight of peanut butter
(g [peanut protein content in grams])b
Pureed fruit or vegetable volume Total volume
1 1 8= teaspoon 0.67 (0.15) 1 2= teaspoon 5 8= teaspoon
2 1 4= teaspoon 1.33 (0.29) 3 4= teaspoon 1 teaspoons
3 1 2= teaspoon 2.67 (0.59) 1 teaspoons 11 2= teaspoons
4 1 teaspoon 5.33 (1.17) 2 teaspoons 3 teaspoonsc
5 11 2= teaspoons 8 (1.6) 4 teaspoons 51 2= teaspoons
Total protein: 3.96 g
aAmounts (volume) of peanut butter measured as teaspoons are approximate measures to keep the dosing as practical as possible
bPeanut protein content is calculated on the average amount of protein for a range of butters using “Report: 16167, USDA Commodity, Peanut Butter, smooth,”
from the USDA Nutrition Database (http://ndb.nal.usda.gov/ndb/foods)
cThree teaspoons = 1 tablespoon
Dose Peanut butter volumea Equivalent weight peanut butter
(g [peanut protein content in grams])b
Volume of hot water Total volume
1 1 8= teaspoon 0.67 (0.15) 1 8= teaspoon 1 4= teaspoon
2 1 4= teaspoon 1.33 (0.29) 1 4= teaspoon 1 2= teaspoon
3 1 2= teaspoon 2.67 (0.59) 1 2= teaspoon 1 teaspoon
4 1 teaspoon 5.33 (1.17) 1 teaspoon 2 teaspoons
5 11 2= teaspoons 8 (1.76) 11 2= teaspoons 3 teaspoons
c
Total protein: 3.96 g
aAmounts (volume) of peanut butter measured as teaspoons are approximate measures to keep the dosing as practical as possible
bPeanut protein content is calculated on the average amount of protein for a range of butters using “Report: 16167, USDA Commodity, Peanut Butter, smooth,”
from the USDA Nutrition Database (http://ndb.nal.usda.gov/ndb/foods)
cThree teaspoons = 1 tablespoon
Dose Peanut flour or peanut butter
powder volumea
Equivalent weight peanut flour or peanut butter
powderb (g [peanut protein content in grams])
Pureed fruit or vegetable
volume
Total volume
1 1 8= teaspoon 0.25 (0.13) 1 2= teaspoon 3 4= teaspoon
2 1 4= teaspoon 0.5 (0.25) 1 teaspoon 11 4= teaspoons
3 1 2= teaspoon 1.0 (0.5) 2 teaspoons 21 2= teaspoons
4 1 teaspoon 2.0 (1.0) 3 teaspoonsc 4 teaspoons
5 2 teaspoons 4.0 (2.0) 6 teaspoonsd 8 teaspoons
Total protein: 3.88 g
aAmounts (volume) of peanut flour or peanut butter powder measured as teaspoons are approximate measures to keep the dosing as practical as possible
bInformation regarding peanut powder and flour reflects averages obtained from the producers. Most brands of peanut flour/peanut butter powder are
approximately 50% peanut protein by weight. However, weight can vary based on the fat content and also the brand chosen. Therefore a weight measurement
can be more accurate than household measurements
cThree teaspoons = 1 tablespoon
dSix teaspoons = 2 tablespoons
Option 3: Measures for peanut flour or peanut butter powder
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Protocol instructions for options 1, 2, and 3
1. Measure peanut butter, peanut flour, or peanut
butter powder for dose 1.
2. Prepare the first dose:
a. If using option 1, add previously tolerated
pureed fruit or vegetable to measured dose 1
peanut butter and stir until well blended. You
can increase or reduce volume of puree to
achieve desired consistency. Note: Increasing the
volume may increase the difficulty of getting
through the entire protocol with a young baby.
b. If using option 2, slowly add hot water to
measured dose 1 peanut butter and stir until
peanut butter is dissolved, thinned, and well
blended. Let the mixture cool. You can increase
water volume (or add previously tolerated infant
cereal) to achieve desired consistency.
c. If using option 3, add previously tolerated
pureed fruit or vegetable to measured dose 1
peanut flour or peanut butter powder and stir
until well blended. You can increase or reduce
volume of puree to achieve desired consistency.
Note: Increasing the volume may increase the
difficulty of getting through entire protocol with
a young baby.
3. Label dose 1.
4. Repeat steps 1 to 3 for the remaining doses 2
through 5, labeling each dose appropriately and
before proceeding to the preparation of the next
dose.
5. Feed dose 1 to infant and observe for symptoms of
reactivity for 15 to 20 min.
6. If no symptoms appear, repeat with dose 2 and
observe for 15 to 20 min.
7. Continue in this manner with doses 3, 4, and 5.
Option 4: Bamba peanut snack (Osem, Israel)
Protocol instructions for option 4
1. Count Bamba sticks for dose 1.
2. Prepare the first dose by slowly adding hot water to
measured Bamba and stirring until Bamba is
dissolved, thinned, well blended, and cooled. You
can increase water volume to achieve desired
consistency. Note: Increasing the volume may
increase the difficulty of getting through the entire
protocol with a young baby.
Dose Bamba,
no. of sticks
Equivalent weight
(peanut protein
content [g])a
Volume of hot water
(approximate, will
need to be adjusted
for each child)
Approximate
final volume
1 1 stick 0.81 (0.1) 1 2= teaspoon 3 4= teaspoons
2 3 sticks 2.43 (0.3) 1 teaspoon 11 2= teaspoons
3 5 sticks 4.05 (0.5) 11 2= teaspoons 21 4= teaspoons
4 10 sticks 8.1 (1.0) 3 teaspoons 4 teaspoons
5 21 sticks 17.01 (2.0) 6 teaspoons 71 2= teaspoons
Total protein:
3.9 g
Note: Other peanut puffs products with equivalent peanut protein content can
be substituted for Bamba
aThe amount of Bamba sticks is an approximate measure looking at a range of
Bamba products. Bamba snacks from different parts of the world have a varied
peanut protein content [30]. The peanut protein content of Bamba was
calculated according to the publication by Du Toit et al. [13]
Table 4 Medication discontinuation considerations before OFC
Medications to be discontinued Last dose before OFC
Cetirizine 5 days
Cyproheptadine 10 days
Diphenhydramine 3 days
Fexofenadine 3 days
Loratadine 7 days
Short-acting bronchodilator (eg, albuterol) 8 h
Medications that can be continued
Antihistamine eye drops
Inhaled/intranasal corticosteroids
Topical (cutaneous) steroids
Topical (cutaneous) pimecrolimus, tacrolimus
Table 5 Emergency medications for a severe reaction during an
office-based infant OFC
Medication Dose
First-line
treatment
Epinephrine
(1:1000 concentration)
0.01 mg/kg IM in the mid-outer
thigh in health care settings
or 0.15 mg of autoinjector
IM in the mid-outer thigh in
community settings Epinephrine
doses may need to be repeated
every 5–15 min
Adjunctive
treatment
Albuterol nebulization 0.15 mg/kg every 20 min × 3
doses (minimum of 2.5 mg per
dose) over 5–15 min
Albuterol MDI
inhalation
2 puffs, 90 μg per puff, with
face mask
Oxygen 8–10 L/min through a face
mask
Diphenhydramine 1.25 mg/kg administered
orally
Cetirizine 2.5 mg administered
orally
Normal saline (0.9%
isotonic solution) or
lactated ringers
20 ml/kg per dose administered
over 5 min intravenously
Steroids Prednisolone 1 mg/kg
administered orally or Solu-
Medrol 1 mg/kg administered
intravenously
IM Intramuscular, MDI metered-dose inhaler
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3. Label dose 1.
4. Repeat steps 1 to 3 for the remaining doses 2
through 5, labeling each dose appropriately
and before proceeding to the preparation of
the next dose.
5. Feed dose 1 to the infant and observe for symptoms
of reactivity for 15 to 20 min.
6. If no symptoms appear, repeat with dose 2 and
observe for 15 to 20 min.
7. Continue in this manner with doses 3, 4, and 5.
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